Genmab — November 2016
-
Ninlaro blev i foråret i første omgang afvis af CHMP i EU. Men er nu taget til nåde. Begrundelsen den gang var: “The CHMP considered that the data from the [TOURMALINE-MM1] study were insufficient to demonstrate a benefit of Ninlaro in the treatment of multiple myeloma. The company had proposed restricting the use of the medicine to patients whose disease is more difficult to treat and had come back after one previous treatment, and to those whose disease had come back after at least two
-
previous treatments. However, the data in these subgroups were not compelling enough and the rationale for assuming greater effectiveness in these patients was not clear.
“Therefore, the CHMP was of the opinion that, based on the currently available data, the benefits of Ninlaro did not outweigh its risks and recommended that it be refused marketing authorization.” -
-
Har lige talt med Nordea ang. Bullx3. De oplyste at der sandsynligvis vil komme til at gå måneder før de lukker op for salg igen.
-
Manglende risikoafdækning.
-
Samme her. De må forvente en væsentlig højere kurs fremadrettet.
-
Tja... ved ikke om de har spurgt
-
Det er ikke korrekt. Kursen er steget med 6.80
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind